Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-08-29 | 2024-11-01 | 236261 |
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-10-04 | 2025-01-10 | 239373 |
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2025-01-30 | 2025-03-28 | 249074 |
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2025-02-06 | 2025-04-04 | 249766 |
| APO-GLIMEPIRIDE | 4MG | TABLET | Resolved | 2017-11-28 | 2019-09-21 | 31007 |
| APO-GLIMEPIRIDE | 1MG | TABLET | Resolved | 2017-12-12 | 2019-09-21 | 32536 |
| APO-GLIMEPIRIDE | 2MG | TABLET | Resolved | 2018-07-11 | 2019-09-21 | 55281 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-06-12 | 2022-07-28 | 162475 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-11 | 2022-08-12 | 164378 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-22 | 2022-08-06 | 165317 |
| APO-GUANFACINE XR | 4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-22 | 2022-08-06 | 165322 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-10-06 | 2024-01-12 | 206579 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-11-06 | 2024-01-12 | 209339 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-08 | 2024-01-12 | 212949 |
| APO-GUANFACINE XR | 4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-15 | 2024-01-12 | 213559 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-22 | 2024-01-12 | 214220 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-22 | 2024-01-12 | 214232 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-12-05 | 2025-01-17 | 244922 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-12-12 | 2025-01-17 | 245496 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-12-12 | 2025-01-17 | 245499 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| MELPHALAN FOR INJECTION | 10ML 50MG | POWDER FOR SOLUTION KIT SOLUTION | Discontinued | 2022-03-23 | 2022-03-23 | 157136 |
| NAPROXEN SODIUM TABLETS | 220MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71228 |
| APO-PENTOXIFYLLINE SR | 400MG | TABLET (EXTENDED-RELEASE) | Discontinued | 2018-10-23 | 2022-01-27 | 65438 |
| APO-TEMAZEPAM | 15MG | CAPSULE | Discontinued | 2018-10-23 | 2019-01-14 | 65477 |
| APO-TEMAZEPAM | 30MG | CAPSULE | Discontinued | 2018-10-23 | 2019-01-07 | 65482 |
| TIGECYCLINE | 50MG | POWDER FOR SOLUTION | To be discontinued | 2019-06-21 | 2019-06-21 | 87218 |